Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANIP NASDAQ:JANX NYSE:MBX NASDAQ:OCUL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANIPANI Pharmaceuticals$63.93+0.9%$64.00$52.50▼$77.00$1.37B0.57303,297 shs318,815 shsJANXJanux Therapeutics$23.56-1.9%$24.74$22.48▼$71.71$1.42B2.86800,036 shs601,583 shsMBXMBX Biosciences$13.75+3.8%$12.25$4.81▼$27.50$459.58MN/A322,395 shs513,171 shsOCULOcular Therapeutix$11.92+2.9%$9.71$5.78▼$12.35$1.84B1.491.98 million shs1.65 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANIPANI Pharmaceuticals+0.92%-5.26%-1.98%-12.36%-2.72%JANXJanux Therapeutics-1.87%-9.24%-2.08%-28.35%-41.97%MBXMBX Biosciences+3.77%-5.63%+11.52%+14.58%+1,374,999,900.00%OCULOcular Therapeutix+2.94%-2.38%+26.00%+35.45%+40.90%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationANIPANI Pharmaceuticals3.6554 of 5 stars2.51.00.03.32.63.31.3JANXJanux Therapeutics2.4087 of 5 stars3.52.00.00.03.61.70.0MBXMBX Biosciences2.6288 of 5 stars3.50.00.00.03.41.70.6OCULOcular Therapeutix3.6116 of 5 stars3.51.00.04.11.92.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANIPANI Pharmaceuticals 3.00Buy$78.8823.38% UpsideJANXJanux Therapeutics 3.08Buy$91.89290.02% UpsideMBXMBX Biosciences 3.00Buy$37.57173.25% UpsideOCULOcular Therapeutix 3.00Buy$17.3345.41% UpsideCurrent Analyst Ratings BreakdownLatest MBX, ANIP, OCUL, and JANX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/16/2025MBXMBX BiosciencesOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$38.007/11/2025JANXJanux TherapeuticsRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$65.007/10/2025ANIPANI PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy ➝ Buy$84.005/29/2025OCULOcular TherapeutixHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.005/12/2025ANIPANI PharmaceuticalsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$86.00 ➝ $86.005/6/2025OCULOcular TherapeutixNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$15.00 ➝ $14.00(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANIPANI Pharmaceuticals$674.07M2.05$7.67 per share8.34$19.11 per share3.35JANXJanux Therapeutics$9.34M149.33N/AN/A$19.49 per share1.21MBXMBX BiosciencesN/AN/AN/AN/AN/AN/AOCULOcular Therapeutix$63.72M29.80N/AN/A$2.01 per share5.93Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANIPANI Pharmaceuticals-$18.52M-$1.27N/A15.19N/A-3.12%21.35%7.52%8/5/2025 (Estimated)JANXJanux Therapeutics-$68.99M-$1.36N/AN/AN/AN/A-9.29%-8.89%8/6/2025 (Estimated)MBXMBX BiosciencesN/AN/A0.00N/AN/AN/AN/AN/AN/AOCULOcular Therapeutix-$193.51M-$1.15N/AN/AN/A-323.09%-59.92%-41.98%8/5/2025 (Estimated)Latest MBX, ANIP, OCUL, and JANX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2025Q2 2025JANXJanux Therapeutics-$0.50N/AN/AN/A$0.30 millionN/A8/5/2025Q2 2025ANIPANI Pharmaceuticals$1.49N/AN/AN/A$187.18 millionN/A8/5/2025Q2 2025OCULOcular Therapeutix-$0.35N/AN/AN/A$13.12 millionN/A5/9/2025Q1 2025ANIPANI Pharmaceuticals$1.37$1.70+$0.33$0.69$179.75 million$197.12 million5/8/2025Q1 2025JANXJanux Therapeutics-$0.43-$0.38+$0.05-$0.38$0.59 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANIPANI PharmaceuticalsN/AN/AN/AN/AN/AJANXJanux TherapeuticsN/AN/AN/AN/AN/AMBXMBX BiosciencesN/AN/AN/AN/AN/AOCULOcular TherapeutixN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANIPANI Pharmaceuticals1.462.661.98JANXJanux TherapeuticsN/A58.4758.47MBXMBX BiosciencesN/AN/AN/AOCULOcular Therapeutix0.2610.2210.14Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANIPANI Pharmaceuticals76.05%JANXJanux Therapeutics75.39%MBXMBX BiosciencesN/AOCULOcular Therapeutix59.21%Insider OwnershipCompanyInsider OwnershipANIPANI Pharmaceuticals11.10%JANXJanux Therapeutics8.10%MBXMBX Biosciences52.19%OCULOcular Therapeutix2.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANIPANI Pharmaceuticals60021.66 million19.26 millionOptionableJANXJanux Therapeutics3059.18 million54.38 millionOptionableMBXMBX Biosciences3633.42 millionN/AN/AOCULOcular Therapeutix230159.30 million155.64 millionOptionableMBX, ANIP, OCUL, and JANX HeadlinesRecent News About These CompaniesOcular Therapeutix (OCUL) Expected to Announce Quarterly Earnings on WednesdayJuly 31 at 7:39 AM | marketbeat.comOcular Therapeutix (NASDAQ:OCUL) Reaches New 12-Month High - What's Next?July 29, 2025 | marketbeat.comBoehringer Ingelheim, Re-Vana Therapeutics to Collaborate on Long-Acting Ophthalmic TherapiesJuly 29, 2025 | pharmtech.comPNottingham Advisors Inc. Has $242,000 Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL)July 28, 2025 | marketbeat.comOcular Therapeutix (NASDAQ:OCUL) Hits New 1-Year High - Here's What HappenedJuly 24, 2025 | marketbeat.comOcular Therapeutix™ to Participate in Upcoming Scientific ConferencesJuly 22, 2025 | globenewswire.comOcular Therapeutix, Inc. (NASDAQ:OCUL) Receives Consensus Recommendation of "Buy" from AnalystsJuly 10, 2025 | marketbeat.comOcular Therapeutix (NASDAQ:OCUL) Shares Up 5.5% - Here's What HappenedJuly 8, 2025 | marketbeat.comOcular Therapeutix (OCUL) Moves 8.6% Higher: Will This Strength Last? - NasdaqJune 27, 2025 | nasdaq.comOcular Therapeutix sharpens focus with retina-centric rebrandJune 27, 2025 | fiercepharma.comFOcular Therapeutix™ Unveils New Corporate Branding, Reflecting its Transformation to a Retina-Focused CompanyJune 26, 2025 | finance.yahoo.comOcular Therapeutixâ„¢ Unveils New Corporate Branding, Reflecting its Transformation to a Retina-Focused CompanyJune 26, 2025 | globenewswire.comOcular Therapeutix (OCUL) Moves 8.6% Higher: Will This Strength Last?June 25, 2025 | zacks.comOcular Therapeutix to present at Clinical Trials at the Summit 2025June 18, 2025 | ophthalmologytimes.comOOcular Therapeutix (NASDAQ:OCUL) shareholders have earned a 33% CAGR over the last three yearsJune 17, 2025 | uk.finance.yahoo.comOcular Therapeutix™ to Participate in Clinical Trials at the Summit (CTS) 2025June 16, 2025 | globenewswire.comQ&A: Justis P. Ehlers, MD, on the Phase 1 HELIOS NPDR trialJune 11, 2025 | ophthalmologytimes.comOOcular Therapeutix closes enrollment in phase 3 SOL-R clinical trial for wet AMDJune 2, 2025 | ophthalmologytimes.comOH.C. Wainwright maintains $15 target on Ocular Therapeutix stockMay 31, 2025 | investing.comDemystifying Ocular Therapeutix: Insights From 7 Analyst ReviewsMay 29, 2025 | benzinga.comOcular Therapeutix chief scientific officer sells $21,712 in stockMay 29, 2025 | investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMBX, ANIP, OCUL, and JANX Company DescriptionsANI Pharmaceuticals NASDAQ:ANIP$63.93 +0.58 (+0.92%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$63.55 -0.38 (-0.59%) As of 08/1/2025 05:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.Janux Therapeutics NASDAQ:JANX$23.56 -0.45 (-1.87%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$23.59 +0.03 (+0.13%) As of 08/1/2025 06:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.MBX Biosciences NYSE:MBX$13.75 +0.50 (+3.77%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$13.72 -0.03 (-0.18%) As of 08/1/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial designed as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies designed as a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide receptor co-agonist prodrug for treating obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.Ocular Therapeutix NASDAQ:OCUL$11.92 +0.34 (+2.94%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$11.92 -0.01 (-0.04%) As of 08/1/2025 06:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale AbbVie Stock Eyes Breakout as Pipeline and Profits Grow Why Bloom Energy Stock Could Break to New Highs Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
